Ricerca avanzata

Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2015 Dicembre;106(6) > Minerva Medica 2015 Dicembre;106(6):333-7



Rivista di Medicina Interna

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

Periodicità: Bimestrale

ISSN 0026-4806

Online ISSN 1827-1669


Minerva Medica 2015 Dicembre;106(6):333-7


The role of mutations and overexpression of the fibroblast growth factor receptor-3 in bladder cancer

Wang QY. 1, Zhao Y. 2, Zhang R. 1

1 Department of Pathology, Affiliated Hospital of Jining Medical University, Shandong, China;
2 Department of Medicine, Orthopedics Hospital of Jining, Shandong, China

Bladder cancer (BC) is the seventh most common cancer worldwide. Throughout the last decade, several studies demonstrated that the fibroblast growth factor (FGF) signalling is altered in a significant proportion of patients with BC. FGF receptor (FGFR) 3 may thus serve as a promising biomarker for BC. Mutations of this gene are prevalent in BC (e.g., found in 74% of non-invasive papillary tumours), suggesting that FGFR3 status is an important event in BC. The aim of this review was to overview the outcomes of different mutations in FGFR3 receptor in the context of BC. We first described FGFR3 receptor and continue with mutations of FGFR3 gene, including activating mutations and overexpression of this gene. Finally, we addressed the clinical relevance of mutated FGFR3 gene.

lingua: Inglese


inizio pagina